# A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

> **NCT02332668** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 370 (estimated)

## Conditions studied

- Melanoma
- Lymphoma
- Solid Tumor
- Classical Hodgkin Lymphoma
- Microsatellite-instability-high Solid Tumor

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02332668
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-03-19
- **Primary completion:** 2028-02-02
- **Final completion:** 2028-02-02
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332668, "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02332668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*